C5 and paroxysmal nocturnal hemoglobinuria: Preliminary clinical data demonstrated that the combination of an anti-C5 antibody and cemdisiran has the potential to address some of the limitations (eg, dosing, breakthrough hemolysis) with currently approved anti-C5 antibody treatments for patients with PNH [18].